Aripiprazole in autism spectrum disorders and fragile X syndrome

Craig A. Erickson, Kimberly A. Stigler, David J. Posey, Christopher J. McDougle

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Autism spectrum disorders (ASDs) are childhood onset developmental disorders characterized by impairment of social skills and repetitive behavior, and also for classic autistic disorder, a significant impairment of communication. In addition to these core symptom domains, persons with ASDs frequently exhibit interfering behavioral symptoms, including irritability marked by aggression, self-injurious behavior, and severe tantrums. Aripiprazole is an atypical or newer generation antipsychotic with a unique mechanism of action impacting dopaminergic and serotonergic neurotransmission. The drug has been found efficacious for several indications, including most recently for use targeting irritability associated with autistic disorder in youth. Fragile X syndrome is the most common inherited cause of developmental disability and the most common known single gene cause of ASDs. As in idiopathic ASDs, irritable behavior is often exhibited by persons with fragile X syndrome. However, research to date in this disorder has not focused on this target symptom cluster. An initial pilot study has begun to assess the impact of aripiprazole on irritability in youth with fragile X syndrome.

Original languageEnglish
Pages (from-to)258-263
Number of pages6
JournalNeurotherapeutics
Volume7
Issue number3
DOIs
StatePublished - 2010

Fingerprint

Fragile X Syndrome
Autistic Disorder
Self-Injurious Behavior
Behavioral Symptoms
Developmental Disabilities
Aggression
Synaptic Transmission
Antipsychotic Agents
Communication
Autism Spectrum Disorder
Aripiprazole
Research
Pharmaceutical Preparations
Genes

Keywords

  • Aripiprazole
  • Autistic disorder
  • Fragile X syndrome
  • Irritability

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Pharmacology
  • Medicine(all)

Cite this

Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J. (2010). Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics, 7(3), 258-263. https://doi.org/10.1016/j.nurt.2010.04.001

Aripiprazole in autism spectrum disorders and fragile X syndrome. / Erickson, Craig A.; Stigler, Kimberly A.; Posey, David J.; McDougle, Christopher J.

In: Neurotherapeutics, Vol. 7, No. 3, 2010, p. 258-263.

Research output: Contribution to journalArticle

Erickson, CA, Stigler, KA, Posey, DJ & McDougle, CJ 2010, 'Aripiprazole in autism spectrum disorders and fragile X syndrome', Neurotherapeutics, vol. 7, no. 3, pp. 258-263. https://doi.org/10.1016/j.nurt.2010.04.001
Erickson, Craig A. ; Stigler, Kimberly A. ; Posey, David J. ; McDougle, Christopher J. / Aripiprazole in autism spectrum disorders and fragile X syndrome. In: Neurotherapeutics. 2010 ; Vol. 7, No. 3. pp. 258-263.
@article{e3ad0637e0a848ef8854d02118e3a550,
title = "Aripiprazole in autism spectrum disorders and fragile X syndrome",
abstract = "Autism spectrum disorders (ASDs) are childhood onset developmental disorders characterized by impairment of social skills and repetitive behavior, and also for classic autistic disorder, a significant impairment of communication. In addition to these core symptom domains, persons with ASDs frequently exhibit interfering behavioral symptoms, including irritability marked by aggression, self-injurious behavior, and severe tantrums. Aripiprazole is an atypical or newer generation antipsychotic with a unique mechanism of action impacting dopaminergic and serotonergic neurotransmission. The drug has been found efficacious for several indications, including most recently for use targeting irritability associated with autistic disorder in youth. Fragile X syndrome is the most common inherited cause of developmental disability and the most common known single gene cause of ASDs. As in idiopathic ASDs, irritable behavior is often exhibited by persons with fragile X syndrome. However, research to date in this disorder has not focused on this target symptom cluster. An initial pilot study has begun to assess the impact of aripiprazole on irritability in youth with fragile X syndrome.",
keywords = "Aripiprazole, Autistic disorder, Fragile X syndrome, Irritability",
author = "Erickson, {Craig A.} and Stigler, {Kimberly A.} and Posey, {David J.} and McDougle, {Christopher J.}",
year = "2010",
doi = "10.1016/j.nurt.2010.04.001",
language = "English",
volume = "7",
pages = "258--263",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Aripiprazole in autism spectrum disorders and fragile X syndrome

AU - Erickson, Craig A.

AU - Stigler, Kimberly A.

AU - Posey, David J.

AU - McDougle, Christopher J.

PY - 2010

Y1 - 2010

N2 - Autism spectrum disorders (ASDs) are childhood onset developmental disorders characterized by impairment of social skills and repetitive behavior, and also for classic autistic disorder, a significant impairment of communication. In addition to these core symptom domains, persons with ASDs frequently exhibit interfering behavioral symptoms, including irritability marked by aggression, self-injurious behavior, and severe tantrums. Aripiprazole is an atypical or newer generation antipsychotic with a unique mechanism of action impacting dopaminergic and serotonergic neurotransmission. The drug has been found efficacious for several indications, including most recently for use targeting irritability associated with autistic disorder in youth. Fragile X syndrome is the most common inherited cause of developmental disability and the most common known single gene cause of ASDs. As in idiopathic ASDs, irritable behavior is often exhibited by persons with fragile X syndrome. However, research to date in this disorder has not focused on this target symptom cluster. An initial pilot study has begun to assess the impact of aripiprazole on irritability in youth with fragile X syndrome.

AB - Autism spectrum disorders (ASDs) are childhood onset developmental disorders characterized by impairment of social skills and repetitive behavior, and also for classic autistic disorder, a significant impairment of communication. In addition to these core symptom domains, persons with ASDs frequently exhibit interfering behavioral symptoms, including irritability marked by aggression, self-injurious behavior, and severe tantrums. Aripiprazole is an atypical or newer generation antipsychotic with a unique mechanism of action impacting dopaminergic and serotonergic neurotransmission. The drug has been found efficacious for several indications, including most recently for use targeting irritability associated with autistic disorder in youth. Fragile X syndrome is the most common inherited cause of developmental disability and the most common known single gene cause of ASDs. As in idiopathic ASDs, irritable behavior is often exhibited by persons with fragile X syndrome. However, research to date in this disorder has not focused on this target symptom cluster. An initial pilot study has begun to assess the impact of aripiprazole on irritability in youth with fragile X syndrome.

KW - Aripiprazole

KW - Autistic disorder

KW - Fragile X syndrome

KW - Irritability

UR - http://www.scopus.com/inward/record.url?scp=77954950453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954950453&partnerID=8YFLogxK

U2 - 10.1016/j.nurt.2010.04.001

DO - 10.1016/j.nurt.2010.04.001

M3 - Article

C2 - 20643378

AN - SCOPUS:77954950453

VL - 7

SP - 258

EP - 263

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 3

ER -